Endovascular Thrombectomy in COVID-19 Infected Patients
Ключови думи
Резюме
Описание
Since the identification of the first case of Severe Acute Respiratory Syndrome (SARS) CoV-2 infection in December 2019 in Wuhan, China, the global number of confirmed COVID-19 cases is roughly 5 000 000, with 216 involved countries. Increasing evidence shows that SARS-CoV-2 may be associated with neurological manifestations, with up to 36% of patients showing neurological symptoms related to the neurovirulence of the SARS-CoV-2.
It has been reported that roughly 5% of COVID-19 infected patients may present acute ischemic stroke (AIS), and these patients may have an unfavorable clinical evolution due to the systemic involvement of the infective disease. In addition, these patients are quite young: the mean age of COVID-19 patients having AIS is lower (56 years), compared to general population of AIS patients (mean age=73 years). Moreover, most of these patients require an intensive care units (ICU) management. Stroke mechanisms may be multiple and can include hypercoagulability from critical illness, cardioembolism from virus-related cardiac injury, and severe inflammation. Indeed, the dysfunction of endothelial cells induced by infection may promote an increased thrombin generation and fibrinolysis; moreover, the hypoxia found in severe COVID-19 patients can be a trigger for thrombosis, increasing blood viscosity, and inducing hypoxia-inducible transcription factors.
Outcomes related to the treatment of COVID-19 patients harboring large vessel occlusion and requiring MT is substantially unknown, but it is likely that the combined morbidity and mortality rate of the two pathologies is high. Accordingly, patient's selection, treatment-management, and results should be urgently elucidated.
Involving 4 different countries (France, Italy, Spain, and US), this multicentric cohort study aims to analyze the largest possible number of COVID-19 infected patients treated with MT for AIS, with the intention to provide treatment-results and neurological outcomes, elucidating the best patient-selection and treatment-management.
Дати
| Последна проверка: | 04/30/2020 |
| Първо изпратено: | 05/25/2020 |
| Очаквано записване подадено: | 05/25/2020 |
| Първо публикувано: | 05/27/2020 |
| Изпратена последна актуализация: | 07/27/2020 |
| Последна актуализация публикувана: | 07/28/2020 |
| Действителна начална дата на проучването: | 03/31/2020 |
| Приблизителна дата на първично завършване: | 06/29/2020 |
| Очаквана дата на завършване на проучването: | 06/29/2020 |
Състояние или заболяване
Интервенция / лечение
Other: Mechanical Trombectomy
Фаза
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
| Полове, допустими за проучване | All |
| Метод за вземане на проби | Probability Sample |
| Приема здрави доброволци | Да |
| Критерии | Inclusion criteria: - Patients >18 years infected with the SARR-CoV-2 with acute ischemic stroke, and eligible for mechanical thrombectomy (based on the current guide-lines) Exclusion criteria: - Patients <18 years ; no eligibility to mechanical thrombectomy ; absence of diagnosis of COVID-19 |
Резултат
Първични изходни мерки
1. Intrahospital mortality [1day]
2. short-term morbidity [1 day]
Вторични изходни мерки
1. Angiographic success [1 day]
